Cogent Biosciences
COGTPhase 3Cogent Biosciences is advancing a pipeline of precision therapies targeting genetically driven diseases, with its lead program bezuclastinib having an FDA New Drug Application accepted with a PDUFA target action date of December 30, 2026. The company operates a discovery organization in Boulder, Colorado, and is led by experienced pharmaceutical executives with expertise in oncology and hematology. Cogent's strategy focuses on improving upon existing drugs with limitations and creating breakthroughs for diseases where adequate solutions are lacking.
COGT · Stock Price
Historical price data
AI Company Overview
Cogent Biosciences is advancing a pipeline of precision therapies targeting genetically driven diseases, with its lead program bezuclastinib having an FDA New Drug Application accepted with a PDUFA target action date of December 30, 2026. The company operates a discovery organization in Boulder, Colorado, and is led by experienced pharmaceutical executives with expertise in oncology and hematology. Cogent's strategy focuses on improving upon existing drugs with limitations and creating breakthroughs for diseases where adequate solutions are lacking.
Technology Platform
Rational design of precision small molecule therapeutics targeting specific genetic mutations that drive disease, leveraging validated biology and focusing on improving upon existing drugs with limitations.
Pipeline Snapshot
1414 drugs in pipeline, 1 in Phase 3
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| CGT9486 plus sunitinib + CGT9486 + Sunitinib + Sunitinib + Midazolam + CGT9486 p... | Advanced Gastrointestinal Stromal Tumors | Phase 3 | |
| Bezuclastinib Tablets (Formulation A) + Bezuclastinib Tablets (Formulation B) + ... | SSM | Phase 2 | |
| Bezuclastinib in combination with sunitinib | Gastrointestinal Stromal Tumors | Phase 2 | |
| bezuclastinib | Advanced Systemic Mastocytosis (AdvSM) | Phase 2 | |
| CGT4859 | Intrahepatic Cholangiocarcinoma (Icc) | Phase 1/2 |
Funding History
4Total raised: $375M
Opportunities
Risk Factors
Competitive Landscape
Cogent faces competition from Blueprint Medicines (avapritinib), Deciphera Pharmaceuticals (ripretinib), and Novartis (midostaurin) in systemic mastocytosis. Differentiation centers on bezuclastinib's selective KIT inhibition profile aiming for improved safety, and the company's precision approach targeting specific genetic mutations rather than broad pathway inhibition.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile